Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Max Scheer

Infectious Disease Woodmere, NY Medical Doctor

NPI 1134298789 CMS profile 141747

15 Irving Place, Woodmere, NY 11598

Open in the dashboard

General payments

$5,541

264 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Max Scheer of Woodmere, NY is reported in the CMS Open Payments database as having received $5,541 across 264 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $586 25
2024 General $483 25
2023 General $628 35
2022 General $617 34
2021 General $683 45
2020 General $770 41
2019 General $1,774 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Max Scheer
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Max Scheer were reported at $586. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Max Scheer Infectious Disease median Middle half National median
2019 $1,774 $190 $60–$862 $163
2020 $770 $124 $32–$606 $114
2021 $683 $148 $38–$905 $132
2022 $617 $166 $50–$834 $149
2023 $628 $171 $57–$787 $160
2024 $483 $176 $52–$752 $164
2025 $586 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $850 23 payments
  2. AbbVie, Inc. $685 39 payments
  3. Amgen Inc. $412 17 payments
  4. Pfizer Inc. $371 21 payments
  5. Novo Nordisk Inc $271 16 payments
  6. GlaxoSmithKline, LLC. $269 15 payments
  7. Merck Sharp & Dohme Corporation $234 14 payments
  8. Sanofi-Aventis U.S. LLC $204 5 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $199 11 payments
  10. Novartis Pharmaceuticals Corporation $195 6 payments
  11. Other $1,851 97 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,530 263 payments
  2. Education $11 1 payment
Products named General payments · program years 2019–2025
  1. LINZESS $354 8 payments
  2. VRAYLAR Neuroscience $291 8 payments
  3. Repatha $251 15 payments
  4. Ozempic $244 14 payments
  5. UBRELVY $220 11 payments
  6. PRALUENT $204 5 payments
  7. TRELEGY ELLIPTA $195 11 payments
  8. VRAYLAR Neuroscience $178 9 payments
  9. VIBERZI $168 3 payments
  10. RYBELSUS $163 10 payments
  11. Other $5,431 290 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 124 drugs

Part D claims

7,447

Median for Internal Medicine: 777

Drug cost

$765,906

Median for Internal Medicine: $73,373

Branded share of claims

17.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 157 $158,950
Jardiance Empagliflozin Brand 95 $121,149
Eliquis Apixaban Brand 96 $93,463
Ozempic Semaglutide Brand 95 $91,537
Xarelto Rivaroxaban Brand 22 $32,537
Januvia Sitagliptin Phosphate Brand 26 $30,634
Efavirenz-Emtric-Tenofov Disop Efavirenz/Emtricit/Tenofovr Df Brand 12 $28,360
Dexlansoprazole Dr Dexlansoprazole Brand 48 $19,339
Edarbi Azilsartan Medoxomil Brand 21 $15,003
Synthroid Levothyroxine Sodium Brand 132 $13,281

The 10 drugs with the highest cost, of 124 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $40
$40 — —
AREXVY
  • GlaxoSmithKline, LLC. $40
$40 — —
Otezla
  • Amgen Inc. $37
$37 — —
Repatha
  • Amgen Inc. $37
$37 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

264 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record